Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook

Laiba Immad

Tue, February 24, 2026 at 6:39 AM GMT+9 2 min read

In this article:

BHC

-2.45%

BLCO

+0.28%

Bausch Health Companies Inc. (NYSE:BHC) is among the 7 Oversold Pharma Stocks to Buy Now.

Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook

Bausch Health Companies Inc. (NYSE:BHC) is one of the most oversold stocks.

TheFly reported on February 19 that Bank of America raised its price target for Bausch + Lomb (BLCO) to $15 from $13 and kept an Underperform rating. The firm pointed out that Bausch + Lomb’s fourth-quarter revenue was 2% more than anticipated and that the company expects the contact lens market to increase by at least 4.5% in 2026. The assessment indicates continued concern regarding BHC’s complete separation, notwithstanding these positives.

Bausch Health Companies Inc. (NYSE:BHC) released its financial results for the fourth quarter and the entire year 2025 on February 18. The company reported consolidated sales of $10.27 billion for the entire year, a 7% increase year over year, and $2.80 billion for the fourth quarter, up 9% from the same period in 2024.

The full-year GAAP net income was $157 million, but the fourth-quarter GAAP statistics revealed a net loss of $112 million. Strong demand for Xifaxan helped the Salix sector continue to drive growth, generating $693 million in Q4 revenue. These outcomes highlight BHC’s continuous operational performance and the beneficial input from its main business divisions.

Bausch Health Companies Inc. (NYSE:BHC) is a global pharmaceutical company specializing in eye care, dermatology, gastrointestinal, and branded generic medicines, providing prescription and over-the-counter products to improve patient health worldwide.

While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

****READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts ****and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.

Terms and Privacy Policy

Privacy Dashboard

More Info